{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-043760","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.426376+00:00","generated_at":"2026-05-30T10:17:49.151994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY","bullets":["GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.","Human Nutrition & Health and Specialty Products segments drove strong sales and earnings growth.","Cash from operations $51.3M; free cash flow $42.2M; repaid $39.6M revolving debt, net debt $153.3M (0.6x leverage).","Launched K2Vital Delta Fermented, VitaCholine Pro-Flo, and AminoShure-XL during the quarter.","Year-to-date 2024 net earnings $94.9M vs $81.9M; net sales $713.7M vs $693.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-043760","json":"https://secwatch.observer/filing/0001628280-24-043760.json","markdown":"https://secwatch.observer/filing/0001628280-24-043760.md","text":"https://secwatch.observer/filing/0001628280-24-043760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828024043760/0001628280-24-043760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828024043760/bcpc-20241025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:17:49.151994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}